Next Generation Sequencing: from Prostate To Colorectal cancer.
Validation of genomic markers for prostate and colorectal cancer.
Human R&D, Diagnostics
Center for Translational Molecular Medicine (CTMM) – Grant ID 03O-402
1 July 2013 to 30 June 2015
In the Western world, both prostate cancer (PCa) and colorectal cancer (CRC) are among the most common cancers and a major leading cause of cancer-related deaths. The PCMM and DeCoDe projects (CTMM funded) identified a number of genomic abnormalities in both types of cancer. As a follow up a spin-off project – NGS-ProToCol was initiated. In particular, NGS-ProToCol aimed to 1) validate the genomic markers identified in PCMM and DeCoDe, and identify novel markers and therapeutic targets, 2) create a reference database, and 3) adopt, adapt and develop tools for the processing and integration of NGS data in collaboration with the CTMM Translational research IT (TraIT) project, and to make all tools and expertise available to the research community. Within the NGS-ProToCol, GenomeScan performed all of the sequencing work using an Ion Proton™ technology.
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. Komor MA, et al. Int J Cancer. 2020 Apr 1;146(7):1979-1992. doi: 10.1002/ijc.32627
Consensus Molecular Subtype Classification of Colorectal Adenomas. Komor MA, et al. The Journal of pathology. 2018 Nov;246(3):266-76. doi: 10.1002/path.5129.
Widespread and functional RNA circularization in localized prostate cancer. Chen S, et al. Cell. 2019 Feb 7;176(4):831-43. doi: 10.1016/j.cell.2019.01.025.
This study was performed within the framework of CTMM, the Center for Translational Molecular Medicine. NGS-ProToCol project (grant 03O-402).